Clobazam for the treatment of intractable epilepsy in children.

Abstract

We describe our experience using clobazam, examining efficacy for individual seizure types and analyzing for factors contributing to initial and sustained response. We retrospectively reviewed medical charts of children treated with clobazam. We collected patient and treatment characteristics and compared response to therapy at 6, 12, and >12 months' duration. One hundred eight patients with a variety of seizure types and etiologies of epilepsy were treated. Response rates for >50% seizure reduction were 59%, 39%, and 30% of patients at 6, 12, and >12 months' therapy, respectively. No seizure type responded more favorably and there were no patient predictors of favorable response. Patients tended to respond early and at low dosing, and half the patients maintained this response for 15 months or more. Clobazam has efficacy against a wide spectrum of seizure types and epilepsy etiologies. An early, low-dose response is a favorable indicator for sustained response.

• Authors: M Scott Perry, Laurie Bailey, Saleem Malik, Courtney Gilson, Amy Kotecha, Angel Hernandez
• Journal: Journal of child neurology (J Child Neurol) Vol. 28 Issue 1 Pg. 34-9 (Jan 2013) ISSN: 1708-8283 [Electronic] United States
• PMID: 23112242 (Publication Type: Journal Article)

Chemical References

• Anticonvulsants
• Benzodiazepines
• Clobazam

Topics

• Adolescent
• Anticonvulsants (therapeutic use)
• Benzodiazepines (therapeutic use)
• Child
• Child, Preschool
• Clobazam
• Epilepsy (classification, drug therapy, etiology)
• Female
• Follow-Up Studies
• Humans
• Infant
• Kaplan-Meier Estimate
• Male
• Retrospective Studies